More on ATR
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $125.77 |
|
|||
| Open | $125.90 | ||||
| 52 Wk High | $81.50 | ||||
| 52 Wk Low | $66.33 | ||||
| Day High | $126.54 | ||||
| Day Low | $125.49 | ||||
| P/E | 49.85 | ||||
| EPS | $2.52 | ||||
| Volume | 448,490 | ||||
- Aptar Pharma wins CE marking for LuerVax intranasal vaccine device
- Aptar Announces CE Marking for LuerVax® and Accompanying Spray Divider, Strengthening Support for Vaccine Developers
- UBS Starts AptarGroup (ATR) at Neutral
- Wells Fargo Assumes AptarGroup (ATR) at Overweight
- Deutsche Bank Starts AptarGroup (ATR) at Buy
- Form 8-K APTARGROUP, INC. For: Sep 21
- Aptar and Mass General Hospital team up on nose-to-brain drug delivery
- Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery
- Form 3 APTARGROUP, INC. For: Sep 11 Filed by: Ackerman Daniel
- Form 8-K APTARGROUP, INC. For: Sep 04
Entities mentioned with ATR
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Definitive Agreement | View Related Stories »
- FDA | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
